InvestSMART

PainChek Ltd (ASX:PCK)

ALERT: Price-sensitive ASX Announcement for PCK
Current share price for PCK : $0.115 -0.035 (-23.33%)+
Announcement
Release
30 Apr 2026 11:18AM
Price at Release
$0.150
Full Release
download
Summary
PainChek Ltd (ASX: PCK) reported significant growth in its March 31, 2026 quarterly activities and cash flow, as outlined in their Appendix 4C report. Key highlights include a master service agreement with Sabra, covering 350 US aged care homes, and a global total of 118,577 contracted licences across aged care facilities with an ARR of $5.9M once fully implemented. The company has $2.3M in cash reserves and anticipates a $1.1M R&D tax refund in Q2 2026. PainChek recorded a 5.4% increase in customer revenue to $2.681M for the nine months ending March 2026 compared to the previous year. The global PainChek assessments have reached 18.8 million, a 97% increase from the previous year, demonstrating strong adoption in markets such as the UK and North America. The company is expanding its partnerships and SaaS model to increase market penetration, with ongoing initiatives to refine its infant app and explore more healthcare professional channels.
Key Points
  • PainChek signed a master service agreement with Sabra for US aged care homes.
  • 118,577 contracted licences with ARR of $5.9M globally.
  • Cash reserves of $2.3 million as of March 31, 2026.
  • R&D tax refund of $1.1 million expected in Q2 2026.
  • Customer revenue increased by 5.4% to $2.681 million for nine months.
  • 18.8 million PainChek assessments conducted globally.
  • Expansion in UK and North America markets with strategic partnerships.
  • Refinement of infant app and exploration of healthcare professional channels.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should refer to the full announcement here for further information.